Tag Archives: NASDAQ:ILMN

Illumina (ILMN) Gets a Buy Rating from Canaccord Genuity

In a report released today, Mark Massaro from Canaccord Genuity maintained a Buy rating on Illumina (ILMN – Research Report), with a price target of $360. The company’s shares closed on Friday at $335.49. Massaro said: “We recently had the

New Buy Rating for Illumina (ILMN), the Healthcare Giant

Canaccord Genuity analyst Mark Massaro maintained a Buy rating on Illumina (ILMN – Research Report) today and set a price target of $350. The company’s shares closed yesterday at $319.20. Massaro observed: “We view Q1 as mixed, but we reiterate

Merrill Lynch Keeps a Buy Rating on Illumina (ILMN)

In a report released today, Derik De Bruin from Merrill Lynch reiterated a Buy rating on Illumina (ILMN – Research Report), with a price target of $355. The company’s shares closed yesterday at $285.26. According to TipRanks.com, Bruin is a

Morgan Stanley Keeps a Hold Rating on Illumina (ILMN)

In a report released today, Steve Beuchaw from Morgan Stanley maintained a Hold rating on Illumina (ILMN – Research Report), with a price target of $288. The company’s shares closed on Friday at $302.69. According to TipRanks.com, Beuchaw is a

Canaccord Genuity Believes Illumina (NASDAQ: ILMN) Still Has Room to Grow

Canaccord Genuity analyst Mark Massaro reiterated a Buy rating on Illumina (NASDAQ: ILMN) yesterday and set a price target of $330. The company’s shares closed yesterday at $301.15, close to its 52-week high of $317.16. According to TipRanks.com, Massaro is

Barclays Sticks to Their Hold Rating for Illumina

In a report released today, Jack Meehan from Barclays maintained a Hold rating on Illumina (NASDAQ: ILMN), with a price target of $235. The company’s shares opened today at $251.99, close to its 52-week high of $256.64. According to TipRanks.com,